The Impact of Obesity and Nutrition on Chronic Liver Diseases, an Issue of Clinics in Liver Disease - Younossi, Zobair
61,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
31 °P sammeln
  • Gebundenes Buch

Internationally renowned experts present topics related to obesity, nutrition, and liver disease in this issue. In the first article, the epidemiology of obesity and its association with liver disease are covered. The following two articles focus on the roles that visceral adipose tissue and microbiota potentially play in the pathogenesis of obesity-related liver disease. The next article focuses on the hepatic pathology seen in patients with obesity-related liver disease and those with malnutrition. The next five articles are focused on NAFLD and provide in-depth data on the natural history…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Internationally renowned experts present topics related to obesity, nutrition, and liver disease in this issue. In the first article, the epidemiology of obesity and its association with liver disease are covered. The following two articles focus on the roles that visceral adipose tissue and microbiota potentially play in the pathogenesis of obesity-related liver disease. The next article focuses on the hepatic pathology seen in patients with obesity-related liver disease and those with malnutrition. The next five articles are focused on NAFLD and provide in-depth data on the natural history and treatment strategies for patients with NAFLD. The next six articles deal with the impact of obesity on other liver diseases and on special populations including children and liver-transplant recipients. The final article provides the most updated information regarding genomics and genetic targets that may provide better prognostic and diagnostic biomarkers and more personalized treatment targets for patients with NAFLD. Cutting-edge information in this issue will help readers gain better understanding of the natural history and pathogenesis of primary and secondary liver diseases associated with obesity. As the information about obesity-related liver disease expands, clinicians will be able to provide more targeted therapeutic options for these patients and develop more accurate diagnostic and prognostic biomarkers.
Autorenporträt
Zobair M. Younossi, is Professor and Chairman of the Global NASH/MASH Council (GNC), Washington, D.C. He earned his medical degree from the University of Rochester (AOA 1989), completed his fellowship training at Scripps Clinic (1989-1995), and obtained a Master of Public Health with multiple honors from San Diego State University (1995). Dr. Younossi began his academic career at the Cleveland Clinic (1995-2000) before establishing the Liver Center and the Beatty Liver and Obesity Research Program at Inova Health System, Virginia. During his tenure at Inova, he held several senior leadership roles, including Chairman of Medicine (2011-2024), President of Inova Medicine (2019-2024), Chairman of Research (2005-2022), and Vice Chairman of the Board of the Inova Foundation (2011-2024). He currently serves as President of the Chronic Liver Disease Foundation (CLDF). A pioneer in MASLD/SLD research, Dr. Younossi has authored over 890 peer-reviewed publications, 1,162 abstracts, and delivered 554 invited lectures worldwide. He is recognized among the most highly cited scholars in liver disease.